Ultralife ULBI

Ultralife FY 2024: revenue $164.5M, up 4%; diluted EPS $0.38

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Ultralife reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$164.5M+4% from $158.6M in FY 202310-K income statement, on EDGAR
  2. Net income$6.3M−12% from $7.2M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$0.38+1167% from $0.03 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$6.9M−33% from $10.2M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations$16.6M+762% from $1.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

Get an email when Ultralife files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3690 and related industry codes: the same peer list as the financial tables.